SCY002P – Method To Treat Gastrointestinal Inflammation

Scythian’s second patent filing covers methods and compositions for treating gastrointestinal inflammation. This includes the use of the cannabinoid CBD, the same CB-2 agonist covered in our concussion treatment combination, together with an NMDA receptor or FAAH inhibitor to control intestinal inflammation in chronic diseases such as irritable bowel syndrome and Crohn’s disease. These diseases are characterized by chronic and sometimes severe inflammation in the gastrointestinal tract caused by an overactive immune system and inflammatory response, due either to autoimmunity or hypersensitivity.